434 related articles for article (PubMed ID: 16788821)
1. Effect of 6-hydroxydopamine treatment on kynurenine aminotransferase-I (KAT-I) immunoreactivity of neurons and glial cells in the rat substantia nigra.
Knyihár-Csillik E; Chadaide Z; Mihály A; Krisztin-Péva B; Fenyo R; Vécsei L
Acta Neuropathol; 2006 Aug; 112(2):127-37. PubMed ID: 16788821
[TBL] [Abstract][Full Text] [Related]
2. Decreased expression of kynurenine aminotransferase-I (KAT-I) in the substantia nigra of mice after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment.
Knyihár-Csillik E; Csillik B; Pákáski M; Krisztin-Péva B; Dobó E; Okuno E; Vécsei L
Neuroscience; 2004; 126(4):899-914. PubMed ID: 15207325
[TBL] [Abstract][Full Text] [Related]
3. Involvement of brain endogenous histamine in the degeneration of dopaminergic neurons in 6-hydroxydopamine-lesioned rats.
Liu CQ; Chen Z; Liu FX; Hu DN; Luo JH
Neuropharmacology; 2007 Dec; 53(7):832-41. PubMed ID: 17919665
[TBL] [Abstract][Full Text] [Related]
4. Increased progenitor cell proliferation and astrogenesis in the partial progressive 6-hydroxydopamine model of Parkinson's disease.
Aponso PM; Faull RL; Connor B
Neuroscience; 2008 Feb; 151(4):1142-53. PubMed ID: 18201835
[TBL] [Abstract][Full Text] [Related]
5. The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.
Datla KP; Bennett RD; Zbarsky V; Ke B; Liang YF; Higa T; Bahorun T; Aruoma OI; Dexter DT
J Pharm Pharmacol; 2004 May; 56(5):649-54. PubMed ID: 15142343
[TBL] [Abstract][Full Text] [Related]
6. Dopamine cell morphology and glial cell hypertrophy and process branching in the nigrostriatal system after striatal 6-OHDA analyzed by specific sterological tools.
Gomide V; Bibancos T; Chadi G
Int J Neurosci; 2005 Apr; 115(4):557-82. PubMed ID: 15804725
[TBL] [Abstract][Full Text] [Related]
7. Osteopontin expression in activated glial cells following mechanical- or toxin-induced nigral dopaminergic cell loss.
Iczkiewicz J; Rose S; Jenner P
Exp Neurol; 2007 Sep; 207(1):95-106. PubMed ID: 17643430
[TBL] [Abstract][Full Text] [Related]
8. Adrenalectomy counteracts the local modulation of astroglial fibroblast growth factor system without interfering with the pattern of 6-OHDA-induced dopamine degeneration in regions of the ventral midbrain.
Chadi G; Silva C; Maximino JR; Fuxe K; da Silva GO
Brain Res; 2008 Jan; 1190():23-38. PubMed ID: 18086466
[TBL] [Abstract][Full Text] [Related]
9. Cytoprotective effects of growth factors: BDNF more potent than GDNF in an organotypic culture model of Parkinson's disease.
Stahl K; Mylonakou MN; Skare Ø; Amiry-Moghaddam M; Torp R
Brain Res; 2011 Mar; 1378():105-18. PubMed ID: 21236244
[TBL] [Abstract][Full Text] [Related]
10. A nitric oxide synthase inhibitor decreases 6-hydroxydopamine effects on tyrosine hydroxylase and neuronal nitric oxide synthase in the rat nigrostriatal pathway.
Gomes MZ; Raisman-Vozari R; Del Bel EA
Brain Res; 2008 Apr; 1203():160-9. PubMed ID: 18313645
[TBL] [Abstract][Full Text] [Related]
11. 1,25-Dihydroxyvitamin D3 administration to 6-hydroxydopamine-lesioned rats increases glial cell line-derived neurotrophic factor and partially restores tyrosine hydroxylase expression in substantia nigra and striatum.
Sanchez B; Relova JL; Gallego R; Ben-Batalla I; Perez-Fernandez R
J Neurosci Res; 2009 Feb; 87(3):723-32. PubMed ID: 18816795
[TBL] [Abstract][Full Text] [Related]
12. Subthalamic nucleus lesioning inhibits expression and phosphorylation of c-Jun in nigral neurons in the rat's 6-OHDA model of Parkinson's disease.
Winter C; Hosmann K; Harnack D; Meissner W; Paul G; Morgenstern R; Kupsch A
Synapse; 2006 Jul; 60(1):69-80. PubMed ID: 16598703
[TBL] [Abstract][Full Text] [Related]
13. The 6-hydroxydopamine-induced nigrostriatal neurodegeneration produces microglia-like NG2 glial cells in the rat substantia nigra.
Kitamura Y; Inden M; Minamino H; Abe M; Takata K; Taniguchi T
Glia; 2010 Nov; 58(14):1686-700. PubMed ID: 20629191
[TBL] [Abstract][Full Text] [Related]
14. KDI tripeptide of gamma1 laminin protects rat dopaminergic neurons from 6-OHDA induced toxicity.
Väänänen AJ; Rauhala P; Tuominen RK; Liesi P
J Neurosci Res; 2006 Aug; 84(3):655-65. PubMed ID: 16810683
[TBL] [Abstract][Full Text] [Related]
15. Human neuromelanin induces neuroinflammation and neurodegeneration in the rat substantia nigra: implications for Parkinson's disease.
Zecca L; Wilms H; Geick S; Claasen JH; Brandenburg LO; Holzknecht C; Panizza ML; Zucca FA; Deuschl G; Sievers J; Lucius R
Acta Neuropathol; 2008 Jul; 116(1):47-55. PubMed ID: 18343932
[TBL] [Abstract][Full Text] [Related]
16. A simple and fast densitometric method for the analysis of tyrosine hydroxylase immunoreactivity in the substantia nigra pars compacta and in the ventral tegmental area.
Xavier LL; Viola GG; Ferraz AC; Da Cunha C; Deonizio JM; Netto CA; Achaval M
Brain Res Brain Res Protoc; 2005 Dec; 16(1-3):58-64. PubMed ID: 16310404
[TBL] [Abstract][Full Text] [Related]
17. NMDA receptors mediate an early up-regulation of brain-derived neurotrophic factor expression in substantia nigra in a rat model of presymptomatic Parkinson's disease.
Bustos G; Abarca J; Bustos V; Riquelme E; Noriega V; Moya C; Campusano J
J Neurosci Res; 2009 Aug; 87(10):2308-18. PubMed ID: 19326433
[TBL] [Abstract][Full Text] [Related]
18. Electrophysiological characterization of substantia nigra dopaminergic neurons in partially lesioned rats: effects of subthalamotomy and levodopa treatment.
Bilbao G; Ruiz-Ortega JA; Miguens N; Ulibarri I; Linazasoro G; Gómez-Urquijo S; Garibi J; Ugedo L
Brain Res; 2006 Apr; 1084(1):175-84. PubMed ID: 16574080
[TBL] [Abstract][Full Text] [Related]
19. Bilobalide inhibits 6-OHDA-induced activation of NF-kappaB and loss of dopaminergic neurons in rat substantia nigra.
Li LY; Zhao XL; Fei XF; Gu ZL; Qin ZH; Liang ZQ
Acta Pharmacol Sin; 2008 May; 29(5):539-47. PubMed ID: 18430361
[TBL] [Abstract][Full Text] [Related]
20. Developing a preclinical model of Parkinson's disease: a study of behaviour in rats with graded 6-OHDA lesions.
Truong L; Allbutt H; Kassiou M; Henderson JM
Behav Brain Res; 2006 Apr; 169(1):1-9. PubMed ID: 16413939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
